Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, R. A.
Right arrow Articles by Rodriguez, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, R. A.
Right arrow Articles by Rodriguez, M.
Neurology 1999;52:386
© 1999 American Academy of Neurology
Brief Communications

Improvement of myelopathy in Sjögren’s syndrome with chlorambucil and prednisone therapy

R. Alan Wright, MB, ChB, MD, FRACP, J. Desmond O’Duffy, MD and Moses Rodriguez, MD

From the Departments of Neurology (Drs. Wright and Rodriguez) and Rheumatology (Dr. O’Duffy), Mayo Clinic, Rochester, MN. Presented at the 50th annual meeting of the American Academy of Neurology; Minneapolis, MN; April 1998.

Address correspondence and reprint requests to Dr. Moses Rodriguez, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; e-mail: rodriguez.moses{at}mayo.edu

The authors present a patient with Sjögren’s syndrome with a fluctuating and then progressive myelopathic syndrome, and optic nerve involvement. Treatment with chlorambucil and prednisone improved the patient’s function from being wheelchair bound to walking unaided. Spinal MRI showed multiple, extensive intraparenchymal areas of abnormal T2-weighted signal intensity, gadolinium enhancement, and cord swelling, which also improved during the period of treatment.




This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
N Sofat and P J Venables
Is Sjogren myelopathy Devic disease?
Ann Rheum Dis, May 1, 2008; 67(5): 730 - 731.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
R. J. Hawley, W. T. Hendricks, C. S. Williams, G. C. Roman, and E. Butler
Treatment of Sjogren Syndrome Myelopathy With Azathioprine and Steroids
Arch Neurol, May 1, 2002; 59(5): 875 - 876.
[Full Text] [PDF]

Home page
 BrainHome page
J. de Seze, T. Stojkovic, G. Breteau, C. Lucas, U. Michon-Pasturel, J.-Y. Gauvrit, E. Hachulla, F. Mounier-Vehier, J.-P. Pruvo, D. Leys, et al.
Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases
Brain, August 1, 2001; 124(8): 1509 - 1521.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
C. S. Williams, E. Butler, and G. C. Roman
Treatment of Myelopathy in Sjogren Syndrome With a Combination of Prednisone and Cyclophosphamide
Arch Neurol, May 1, 2001; 58(5): 815 - 819.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.